# Hope S. Rugo

Source: https://onco.cc/people/hope-rugo/  
OnCo record `hope-rugo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Breast oncologist who led key ADC and CDK4/6 trials and moved from UCSF to City of Hope in 2024.

## Summary

Hope Rugo is Division Chief of Breast Medical Oncology and Director of the Women's Cancers Program at City of Hope, which she joined from UCSF in 2024. A breast medical oncologist specialising in antibody-drug conjugates and supportive care, she was principal investigator of TROPiCS-02, the trial of sacituzumab govitecan in hormone receptor-positive breast cancer, and a leader in scalp cooling and toxicity management studies. Her papers report sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer in the Journal of Clinical Oncology and the association between scalp cooling device use and alopecia after chemotherapy in JAMA. Her work links TROP2, palbociclib and cold cap scalp cooling.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Division Chief, Breast Medical Oncology; Director, Women's Cancers Program, City of Hope
- Specialisms: Breast cancer; ADCs; Supportive care

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hope_Rugo
- City of Hope research faculty: https://www.cityofhope.org/research/find-a-researcher
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Rugo%20HS%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Hope%20S.%20Rugo

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Palbociclib](https://onco.cc/drugs/palbociclib/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- institutions: [City of Hope](https://onco.cc/institutions/city-of-hope/)
- trials: [TROPiCS-02](https://onco.cc/trials/tropics-02/)
- key papers: [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/), [Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial](https://onco.cc/key-papers/paper-geyer-brightness-4-year-follow-up-ann-oncol-2022/), [PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-rugo-pd-l1-assay-comparison-impassion130-jnci-2021/), [Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer](https://onco.cc/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/hope-rugo.json